NASDAQ:AXGN AxoGen (AXGN) Stock Price, News & Analysis $40.26 +0.78 (+1.98%) Closing price 07/21/2026 04:00 PM EasternExtended Trading$40.26 0.00 (0.00%) As of 07/21/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About AxoGen Stock (NASDAQ:AXGN) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get AxoGen alerts:Sign Up Key Stats Today's Range$39.56▼$40.8750-Day Range$38.72▼$46.1952-Week Range$11.61▼$46.95Volume1.24 million shsAverage Volume1.46 million shsMarket Capitalization$2.14 billionP/E RatioN/ADividend YieldN/APrice Target$46.50Consensus RatingModerate Buy Company Overview AxoGen, Inc. is a Florida-based medical technology company that develops and commercializes surgical solutions for peripheral nerve damage. Founded in 2002 and headquartered in Alachua, Florida, the company focuses on restoring nerve function and improving patient outcomes through innovative biologic and engineered products. AxoGen’s offerings address a range of traumatic and iatrogenic injuries, offering alternatives to traditional nerve autografts. The company’s core product portfolio includes the Avance® Nerve Graft, a decellularized human nerve allograft designed to bridge nerve gaps without the need for a secondary harvest site, and the Axoguard® Nerve Connector and Protector devices, which facilitate nerve coaptation and protect repaired sites from surrounding scar tissue. These proprietary platforms are supported by a direct sales force in the United States and strategic distributor partnerships in international markets. AxoGen markets its technologies across North America, Europe, Australia and parts of Latin America, collaborating with surgeons in specialties such as hand, orthopedics, plastic and reconstructive surgery. The company leverages clinical training programs, peer-reviewed research and reimbursement support services to drive adoption of its nerve repair solutions. As it advances its product pipeline, AxoGen continues to seek regulatory clearances and expand its global footprint in the evolving field of peripheral nerve repair.AI Generated. May Contain Errors. Read More AxoGen Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks59th Percentile Overall ScoreAXGN MarketRank™: AxoGen scored higher than 59% of companies evaluated by MarketBeat, and ranked 731st out of 1,682 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingModerate Buy Consensus RatingAxoGen has received a consensus rating of Moderate Buy. The company's average rating score is 2.73, and is based on no strong buy ratings, 9 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialAxoGen has a consensus price target of $46.50, representing about 15.5% upside from its current price of $40.26.Amount of Analyst CoverageAxoGen has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about AxoGen's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for AxoGen are expected to grow in the coming year, from ($0.37) to $0.27 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of AxoGen is -62.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of AxoGen is -62.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAxoGen has a P/B Ratio of 14.43. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about AxoGen's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted8.93% of the float of AxoGen has been sold short.Short Interest Ratio / Days to CoverAxoGen has a short interest ratio ("days to cover") of 2.85, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in AxoGen has recently increased by 26.51%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAxoGen does not currently pay a dividend.Dividend GrowthAxoGen does not have a long track record of dividend growth. News and Social Media3.6 / 5News Sentiment0.77 News SentimentAxoGen has a news sentiment score of 0.77. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.66 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for AxoGen this week, compared to 4 articles on an average week.Search Interest15 people have searched for AXGN on MarketBeat in the last 30 days. This is an increase of 650% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added AxoGen to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership1.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, AxoGen insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,268,792.00 in company stock.Percentage Held by Insiders2.44% of the stock of AxoGen is held by insiders.Percentage Held by Institutions80.29% of the stock of AxoGen is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about AxoGen's insider trading history. Receive AXGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for AxoGen and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. AXGN Stock News HeadlinesAxoGen (NASDAQ:AXGN) Lowered to Hold Rating by Wall Street ZenJuly 18, 2026 | americanbankingnews.comAxogen, Inc. to Report Second Quarter 2026 Financial Results on July 29, 2026July 15, 2026 | globenewswire.comThe Starlink of EnergyA portable energy unit - already used by the U.S. Navy for decades - is now drawing serious attention from Big Tech and Washington policymakers. It can be trucked to a data center, military base, or industrial site and deliver reliable power for years without grid access. A key government milestone expected this August could bring significant visibility to this space. One small stock sits at the center of it. | Monument Traders Alliance (Ad)AxoGen (NASDAQ:AXGN) Shares Down 6.7% - Here's WhyJuly 12, 2026 | americanbankingnews.comAxoGen, stock of the day, offers entry after bullish reboundJune 5, 2026 | msn.comAxoGen, Stock Of The Day, Offers Entry After Bullish ReboundJune 5, 2026 | investors.comAxogen Inc.May 18, 2026 | money.usnews.comAxogen (AXGN) price target increased by 16.82% to 51.71May 15, 2026 | msn.comSee More Headlines AXGN Stock Analysis - Frequently Asked Questions How have AXGN shares performed this year? AxoGen's stock was trading at $32.73 on January 1st, 2026. Since then, AXGN stock has increased by 23.0% and is now trading at $40.26. How were AxoGen's earnings last quarter? AxoGen, Inc. (NASDAQ:AXGN) posted its quarterly earnings data on Tuesday, April, 28th. The medical equipment provider reported $0.07 earnings per share for the quarter, missing the consensus estimate of $0.12 by $0.05. The medical equipment provider earned $61.46 million during the quarter, compared to analyst estimates of $57.85 million. AxoGen had a negative net margin of 13.21% and a negative trailing twelve-month return on equity of 9.63%. Read the conference call transcript. Who are AxoGen's major shareholders? Top institutional shareholders of AxoGen include Wasatch Advisors LP (2.44%), Assenagon Asset Management S.A. (1.96%) and MFG Wealth Management Inc. (0.05%). Insiders that own company stock include Karen L Zaderej, Gregory Gene Freitag, Erick Wayne Devinney, Amy Mcbride Wendell, Michael D Dale, Guido J Neels, Peter J Mariani, Michael Patrick Donovan, Marc A Began, Lindsey Marie Hartley, Kathy Johnson Weiler, Paul Thomas, John Johnson, William P Mr Burke and Joseph A Tyndall. View institutional ownership trends. How do I buy shares of AxoGen? Shares of AXGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of AxoGen own? Based on aggregate information from My MarketBeat watchlists, some other companies that AxoGen investors own include American Water Works (AWK), Waste Connections (WCN), The RMR Group (RMR), DiamondRock Hospitality (DRH), AUO (AUOTY), iShares Micro-Cap ETF (IWC) and Voyager Therapeutics (VYGR). Company Calendar Last Earnings4/28/2026Today7/21/2026Next Earnings (Estimated)7/29/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (11m+) 1-Year History Jul 25 Oct 25 Jan 26 Apr 26 Jul 26 AXGN's financial health is in the Green zone, according to TradeSmith. AXGN has been in this zone for over 11 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED INSTRUMENTS Sub-IndustryMedical Equipment Current SymbolNASDAQ:AXGN CIK805928 Webwww.axogeninc.com Phone(386) 462-6800Fax386-462-6801Employees450Year Founded2002Price Target and Rating Average Price Target for AxoGen$46.50 High Price Target$50.00 Low Price Target$36.00 Potential Upside/Downside+15.5%Consensus RatingModerate Buy Rating Score (0-4)2.73 Research Coverage11 Analysts Profitability EPS (Trailing Twelve Months)($0.64) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$15.70 million Net Margins-13.21% Pretax Margin-13.21% Return on Equity-9.63% Return on Assets-6.26% Debt Debt-to-Equity Ratio0.08 Current Ratio7.10 Quick Ratio5.33 Sales & Book Value Annual Sales$225.21 million Price / Sales9.51 Cash FlowN/A Price / Cash FlowN/A Book Value$2.79 per share Price / Book14.43Miscellaneous Outstanding Shares53,180,000Free Float51,880,000Market Cap$2.14 billion OptionableOptionable Beta1.09 Social Links 7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free Report This page (NASDAQ:AXGN) was last updated on 7/22/2026 by MarketBeat.com Staff. From Our PartnersThe options guide that actually starts at the beginningMost options educators jump straight into Greeks, spreads, and implied volatility - losing beginners before th...Base Camp Trading | SponsoredBlackRock is hoarding it. JPMorgan is hoarding it. Do you own it?BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredElon says “don’t save money.” Is he right?Robert Kiyosaki, author of Rich Dad Poor Dad, says you don't have to wait for Elon Musk's vision of universal ...Freedom Financial | SponsoredThe Starlink of EnergyA portable energy unit - already used by the U.S. Navy for decades - is now drawing serious attention from Big...Monument Traders Alliance | SponsoredOxford Club Analyst’s Urgent AI WarningAlexander Green, Chief Investment Strategist at The Oxford Club, is sharing a private presentation with a warn...The Oxford Club | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | Sponsored30-Year market veteran reveals America’s #1 StockMarket veteran Jim Woods has flagged triple-digit gains multiple times in under two months - 151% on Netflix, ...Eagle Publishing | SponsoredNot oil. Not solar. Bigger.The International Energy Agency measured it at 140 times global electricity demand. It runs 24 hours a day, pr...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AxoGen, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AxoGen With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
